LSK BIOPHARMA RECEIVES APPROVAL TO INITIATE PHASE 3 FROM KOREA’S MFDS, EXPECTS FIRST-PATIENT-ENROLLED IN GLOBAL PHASE 3 SHORTLY
SALT LAKE CITY, January 6, 2017 – LSK BioPharma (LSKB) today announced that it received approval for its apatinib phase 3 protocol under the Korean Ministry of Food and Drug Safety (MFDS). South Korea will be a part of the